Apellis Pharmaceuticals (APLS) Earns Buy Rating from Analysts at Citigroup

Citigroup began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a report published on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.

Separately, J P Morgan Chase & Co assumed coverage on Apellis Pharmaceuticals in a report on Monday. They set an overweight rating and a $31.00 target price for the company.

Shares of Apellis Pharmaceuticals (NASDAQ APLS) opened at $13.60 on Monday. Apellis Pharmaceuticals has a twelve month low of $12.45 and a twelve month high of $15.41.

In other Apellis Pharmaceuticals news, major shareholder Global Strategic Fund I. Venbio acquired 127,515 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $1,785,210.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

WARNING: This article was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.thelincolnianonline.com/2017/12/07/apellis-pharmaceuticals-apls-earns-buy-rating-from-analysts-at-citigroup.html.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.

Receive News & Ratings for Apellis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply